• 6737 Citations
  • 39 Scopus h-Index
1981 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Rhabdomyosarcoma Medicine & Life Sciences
Osteosarcoma Medicine & Life Sciences
Vincristine Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Ifosfamide Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Cyclophosphamide Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1981 2002

CHILDRENS CANCER GROUP

Arndt, C. A. S.

National Institutes of Health

1/1/8111/30/02

Project: Research project

Neoplasms
Epidemiology
Research Personnel
Pharmacology
Committee Membership

Research Output 1986 2019

  • 6737 Citations
  • 39 Scopus h-Index
  • 111 Article
  • 7 Review article
  • 4 Letter
  • 2 Comment/debate
1 Citation (Scopus)

Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group

Casey, D. L., Chi, Y. Y., Donaldson, S. S., Hawkins, D. S., Tian, J., Arndt, C. A. S., Rodeberg, D. A., Routh, J. C., Lautz, T. B., Gupta, A. A., Yock, T. I. & Wolden, S. L., Jan 1 2019, In : Cancer.

Research output: Contribution to journalArticle

Rhabdomyosarcoma
Cyclophosphamide
Radiotherapy
Clinical Trials
irinotecan

On the First Usage of the Term “Rhabdomyosarcoma”

Raney, R. B., Arndt, C. A. S. & Parham, D. M., Jan 1 2019, In : Pediatric and Developmental Pathology. 22, 1, 1 p.

Research output: Contribution to journalLetter

Rhabdomyosarcoma
4 Citations (Scopus)

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Smeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D., Gorlick, R., Janeway, K. A., Ingleby, F. C., Anninga, J., Antal, I., Arndt, C. A. S., Brown, K. L. B., Butterfass-Bahloul, T., Calaminus, G., Capra, M., Dhooge, C., Eriksson, M., Flanagan, A. M., Friedel, G. & 32 othersGebhardt, M. C., Gelderblom, H., Goldsby, R., Grier, H. E., Grimer, R., Hawkins, D. S., Hecker-Nolting, S., Sundby Hall, K., Isakoff, M. S., Jovic, G., Kühne, T., Kager, L., von Kalle, T., Kabickova, E., Lang, S., Lau, C. C., Leavey, P. J., Lessnick, S. L., Mascarenhas, L., Mayer-Steinacker, R., Meyers, P. A., Nagarajan, R., Randall, R. L., Reichardt, P., Renard, M., Rechnitzer, C., Schwartz, C. L., Strauss, S., Teot, L., Timmermann, B., Sydes, M. R. & Marina, N., Mar 1 2019, In : European Journal of Cancer. 109, p. 36-50 15 p.

Research output: Contribution to journalArticle

Osteosarcoma
Cohort Studies
Confidence Intervals
Survival
Neoplasm Metastasis
10 Citations (Scopus)

Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: A report from the children’s oncology group

Hawkins, D. S., Chi, Y. Y., Anderson, J. R., Tian, J., Arndt, C. A. S., Bomgaars, L., Donaldson, S. S., Hayes-Jordan, A., Mascarenhas, L., Mccarville, M. B., Mccune, J. S., Mccowage, G., Million, L., Morris, C. D., Parham, D. M., Rodeberg, D. A., Rudzinski, E. R., Shnorhavorian, M., Spunt, S. L., Skapek, S. X. & 4 othersTeot, L. A., Wolden, S., Yock, T. I. & Meyer, W. H., Sep 20 2018, In : Journal of Clinical Oncology. 36, 27, p. 2770-2777 8 p.

Research output: Contribution to journalArticle

irinotecan
Rhabdomyosarcoma
Dactinomycin
Vincristine
Cyclophosphamide
1 Citation (Scopus)

Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned

Arndt, C. A. S., Bisogno, G. & Koscielniak, E., Jul 1 2018, In : Cancer Treatment Reviews. 68, p. 94-101 8 p.

Research output: Contribution to journalReview article

Rhabdomyosarcoma
Alkylating Agents
Drug Therapy
Ifosfamide
Dactinomycin